

# **Product** Data Sheet

## SRP-5051 sodium

Cat. No.: HY-132585A

Molecular Formula:  $C_{404}H_{616}N_{202}Na_{30}O_{130}P_{30}$ 

Molecular Weight: 12001.37

Target: Others SRP-5051 (sodium)

Pathway: Others

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

### **BIOLOGICAL ACTIVITY**

Description

SRP-5051 sodium is a next-generation antisense oligonucleotide of peptide phosphorodiamidate morpholino oligomer (PPMO). SRP-5051 targeting exon 51 skipping in Duchenne muscular dystrophy (DMD)<sup>[1]</sup>.

#### **REFERENCES**

[1]. Sarepta Therapeutics reports positive clinical results from phase 2 MOMENTUM study of SRP-5051 in patients with Duchenne muscular dystrophy amenable to skipping exon 51. News release. Sarepta Therapeutics. May 3, 2021. Accessed May 4, 2021.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

**Screening Libraries** 

Inhibitors

**Proteins**